Novartis Q1 2023 Earnings Report $97.11 +0.34 (+0.35%) (As of 12/20/2024 04:33 PM ET) Earnings HistoryForecast Novartis EPS ResultsActual EPS$1.71Consensus EPS $1.55Beat/MissBeat by +$0.16One Year Ago EPS$1.46Novartis Revenue ResultsActual Revenue$12.95 billionExpected Revenue$12.60 billionBeat/MissBeat by +$354.31 millionYoY Revenue Growth+3.40%Novartis Announcement DetailsQuarterQ1 2023Date4/25/2023TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptNVS Earnings History Your chance to get on the next “60-Second Trade” (Ad)Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!Just head over here! Novartis Earnings HeadlinesBrokerages Set Novartis AG (NYSE:NVS) Target Price at $121.50December 21 at 1:34 AM | americanbankingnews.comSome 330 jobs hit as Novartis closes Morphosys, WiWo reportsDecember 19 at 5:21 AM | reuters.comTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… December 21, 2024 | Crypto 101 Media (Ad)BioAge Labs announces multi-year collaboration with NovartisDecember 18 at 7:48 PM | markets.businessinsider.comEast Bay aging-focused drug company lands new partner, potential half-billion-dollar payoutDecember 18 at 7:48 PM | bizjournals.comNovartis AG (NVS): Among the Oversold Global Stocks to Buy Right NowDecember 18 at 8:16 AM | insidermonkey.comSee More Novartis Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Novartis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Novartis and other key companies, straight to your email. Email Address About NovartisNovartis (NYSE:NVS) engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.View Novartis ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
